Physician profile
Jun Oh Kim
NPI 1245295765
$5,364.94
in general payments reported to CMS, 2019-2025
24 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $251 · 2021: $113 · 2022: $169 · 2023: $788 · 2024: $1,492 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,441.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,071.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $800.07 | 2022-2025 | |
| Novo Nordisk INC | $737.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $708.22 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $529.17 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $512.40 | 2019-2025 | |
| Lilly USA, LLC | $168.09 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $153.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.69 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $115.08 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $87.36 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $65.16 | 2019-2024 | Veozah |
| Dynavax Technologies Corporation | $41.93 | 2024 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $34.75 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $34.65 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $33.83 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $28.95 | 2019 | |
| Idorsia Pharmaceuticals US INC | $22.78 | 2023 | Quviviq |
| Medtronic, INC. | $18.58 | 2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $17.15 | 2024 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.85 | 2019 | |
| Abbott Laboratories | $14.14 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $13.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.